---
title: Donor cell injections reduce tremor
nct_id: NCT06978920
phase: PHASE1
status: RECRUITING
sponsor: Nuwacell Biotechnologies Co., Ltd.
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06978920"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06978920"
last_fetched: "2026-05-10T14:07:46.316Z"
source: "Parkinson's Pathways (curated)"
---
# Donor cell injections reduce tremor

**Goal (in five words):** Donor cell injections reduce tremor

**Official Title:** A Phase I, Open Label, Single Arm, Dose Escalation and Dose Expansion Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Human Induced Pluripotent Stem Cell Derived Dopaminergic Progenitor Cells (NCR201) Injection in the Treatment of Subjects With Parkinson's Disease

**Trial ID:** [NCT06978920](https://clinicaltrials.gov/study/NCT06978920)

## Key Facts

- **Phase:** PHASE1
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Nuwacell Biotechnologies Co., Ltd.
- **Target Enrollment:** 48 participants
- **Start Date:** 2025-06-06
- **Completion Date:** 2026-07-01
- **Conditions:** Parkinson Disease
- **Interventions:** Allogeneic dopaminergic neural precursor cell(NCR201)
- **Intervention Types:** DRUG

## Summary For Families

A Phase 1 effort to see if giving lab-made, donor-derived dopamine progenitor cells can be safely tolerated and show early signs of replacing the lost dopamine neurons that cause Parkinson's symptoms. The treatment is an injection of human induced pluripotent stem cell derived dopaminergic precursor cells, meant to engraft in the brain and produce dopamine to supplement existing levodopa or other dopamine therapies, with the main goals of checking safety, tolerability, and any initial benefit. The trial seeks people 40 to 75 years old with Parkinson's for more than five years who are on a stable dose of dopamine medication and can have PET/CT/MRI, and excludes those with prior brain surgery, prior stem cell therapy, significant cognitive or psychiatric problems, serious systemic illness, or a history of metastatic cancer.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 75 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Ages between 40 and 75 years;
* Diagnosed to be Parkinson's disease according to Parkinson's disease diagnostic criteria;
* Disease history over 5 years;
* Stable dose of dopamine treatment;
* Able to undergo PET/CT/MRI detection;

Exclusion Criteria:

* Patients who have previously undergone brain surgery;
* Past use of stem cell therapy or participation in stem cell clinical research;
* Cognitive impairment;
* History of mental disorders;
* Patients with other serious systemic diseases;
* Past or current metastatic malignant tumors.
```

## Locations (1)

- The First Affiliated Hospital of USTC, Hefei, Anhui, China _(31.8639, 117.2808)_
  - The First Affiliated Hospital of USTC — (CONTACT) — 0551-96512 — ahslyyxcb@163.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06978920*  
*HTML version: https://parkinsonspathways.com/trial/NCT06978920*  
*Source data: https://clinicaltrials.gov/study/NCT06978920*